Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The interest in using L-asparaginase in pancreatic cancer arose from in vitro and in vivo
studies data showing an anti-neoplastic effect on pancreatic tumor cell lines. Interestingly,
these studies suggest an additional effect of L-asparaginase associated to gemcitabine.GRASPA
is a suspension of red blood cells encapsulating L-asparaginase. The aim of this phase I
clinical trial is to evaluate the Maximum Tolerated Dose (MTD) of GRASPA on locally advanced
or metastatic pancreatic tumors, after therapy failure of first or second line chemotherapy
using gemcitabine.